Metastatic urothelial carcinoma (mUC) is a common tumor associated with high mortality. To date, the standard chemotherapy-based treatment has yielded suboptimal outcomes, characterized by limited survival and a substantial impact on patients’ quality of life. The introduction of new therapies has significantly improved overall survival (OS) and progression-free survival (PFS) rates. However, bringing novel treatments into clinical practice comes with an unfamiliar toxicity profile that may influence the choice of systemic therapy. The aim of this review is to analyze the toxicity of these new therapies and reflect on the role of appropriate management in treatment selection and planning of therapeutic sequencing in patients with mUC.
转移性尿路上皮癌（mUC）是一种常见且死亡率较高的肿瘤。迄今为止，以化疗为基础的标准治疗方案效果欠佳，表现为生存期有限且对患者生活质量影响显著。新型疗法的引入显著提高了总生存期（OS）和无进展生存期（PFS）。然而，这些新疗法在临床应用中呈现出不熟悉的毒性特征，可能影响全身治疗方案的选择。本综述旨在分析这些新疗法的毒性，并探讨合理管理在mUC患者治疗选择及治疗序贯规划中的作用。
肿瘤(癌症)患者之家